H19 in Acute Lymphoblastic Leukemia.

Launched by ASSIUT UNIVERSITY · Jul 11, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on studying a gene called H19 in patients with Acute Lymphoblastic Leukemia (ALL), a type of cancer that affects the blood and bone marrow. Researchers want to measure how much of the H19 gene is present in samples taken from patients who have just been diagnosed with this condition. By comparing the levels of this gene with the patients' clinical symptoms and lab results, the study aims to understand more about how H19 might relate to the disease.

To participate in this trial, patients must be newly diagnosed with ALL. However, individuals who have other blood disorders, a history of different cancers, or are currently undergoing chemotherapy or radiation treatment will not be eligible. This trial is not yet recruiting participants, so there’s still time to learn more and consider if this research is right for you or a loved one.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Newly diagnosed ALL patients.
• Exclusion Criteria:
• • - 1-Presence of other haematological disorders, history of other malignancies or relapsed ALL.
• • 2-Patients under chemotherapy or radiotherapy.